เอกสารอ้างอิง
[1]. สมาคมโรคเบาหวานแห่งประเทศไทย. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน 2560 (Clinical Practice Guideline for Diabetes 2017). กรุงเทพฯ: สมาคมโรคเบาหวานแห่งประเทศไทย; 2560.
[2]. De Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 Nov.; 102(5): 974-89.
[3]. U.S. Food & Drug Administration. JARDIANCE® (empagliflozin) tablets, for oral use [online]. Available from: https://www.accessdata.fda.gov.
[4]. Empagliflozin. In: Specipic Lexicomp Online Database [database on the Internet]. Hudson (OH): Lexicomp Inc.: 2023; cite 1 Feb. 2023. Available from: http://online .Lexi.com.
[5]. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4S): S1-S115.
[6]. American Diabetes Association. Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45(Suppl.1): S1-S264.
[7]. Tuttle KR, Levin A, Nangaku M, et al. Safety of Empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical rials. Diabetes Care. 2022; 45(6): 1445-52.
[8]. นวพร อัศวศักดิ์สกุล, ขจร ตีรณธนากุล. Sugar and kidney, the new era for SGLT2 inhibitor. วารสารสมาคมโรคไตแห่งประเทศไทย. 2561 ก.ค.-ก.ย.; 24(3): 12-9.
[9]. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 May.; 2(5): 369-84.
[10]. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2023 Jan. 12; 388(2): 117-27.